Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
November 27 2017 - 7:05AM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat progressive non-viral liver diseases, today
announced the appointment of Christian Weyer, M.D., M.A.S., as
Executive Vice President, Research & Development, reporting to
Dr. Mark Pruzanski, President and CEO. Dr. David Shapiro will
continue in his role as Chief Medical Officer.
“Chris brings more than 20 years of experience
in metabolic drug development to the executive management team at
Intercept,” said Dr. Pruzanski. “His track record of managing
global clinical development programs and strategic partnerships,
combined with his clinical trial experience that spans all stages
of product development and the continuum of diabetes, obesity and
NASH, makes Chris ideally suited to lead our R&D organization
moving forward.”
Dr. Weyer most recently served as President and
Chief Development Officer of ProSciento, a clinical research and
development service provider focused on diabetes, obesity,
nonalcoholic fatty liver disease and NASH. Prior to ProSciento, Dr.
Weyer held executive leadership roles as President and CEO of Fate
Therapeutics and as Senior Vice President of Research &
Development, among other leadership roles of increasing
responsibility, at Amylin Pharmaceuticals. Earlier in his career,
Dr. Weyer held positions at the National Institutes of Health and
the Department of Metabolic Disorders at the University of
Düsseldorf, Germany.
“Building on a strong scientific foundation with
compelling clinical evidence, Intercept is leading the industry’s
most advanced clinical development program in NASH, a prevalent and
serious disorder with global health-economic impact and no
currently available pharmacological treatment options,” said Dr.
Weyer. “I am thrilled to be joining the company at such a
significant juncture and look forward to helping advance its
mission of bringing innovative new treatments to patients around
the world who are living with progressive non-viral liver diseases
with high unmet needs.”
About Intercept
Intercept is a biopharmaceutical company focused
on the development and commercialization of novel therapeutics to
treat progressive non-viral liver diseases, including primary
biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH),
primary sclerosing cholangitis (PSC) and biliary atresia. Founded
in 2002 in New York, Intercept now has operations in the United
States, Europe and Canada. For more information, please visit
www.interceptpharma.com or connect with the company on Twitter and
LinkedIn.
About Nonalcoholic
Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious
progressive liver disease caused by excessive fat accumulation in
the liver that induces chronic inflammation, resulting in
progressive fibrosis (scarring) that can lead to cirrhosis,
eventual liver failure, cancer and death. There are currently no
medications approved for the treatment of NASH. The proportion of
liver transplants attributable to NASH has increased rapidly in
past years and by 2020 the disease is projected to become the
leading indication for liver transplant.
Safe Harbor Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, our strategic
directives under the caption "About Intercept." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of
important risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the potential
benefit and commercial potential of Ocaliva in PBC, and Intercept's
ability to maintain its regulatory approval in jurisdictions in
which Ocaliva is approved for use in PBC; the initiation, cost,
timing, progress and results of Intercept's development activities,
preclinical studies and clinical trials; the timing of and
Intercept's ability to obtain and maintain regulatory approval of
OCA in PBC in countries outside the ones in which it is approved
and in indications other than PBC and any other product candidates
it may develop; conditions that may be imposed by regulatory
authorities on Intercept's marketing approvals for its products and
product candidates such as the need for clinical outcomes data (and
not just results based on achievement of a surrogate endpoint), and
any related restrictions, limitations, and/or warnings in the label
of any approved products and product candidates; Intercept's plans
to research, develop and commercialize its product candidates;
Intercept's ability to obtain and maintain intellectual property
protection for its products and product candidates; Intercept's
ability to successfully commercialize its products and product
candidates; the size and growth of the markets for Intercept's
products and product candidates and its ability to serve those
markets; the rate and degree of market acceptance of any of
Intercept's products, which may be affected by the reimbursement
received from payors; the success of competing drugs that are or
become available; regulatory developments in the United States and
other countries; the performance of third-party suppliers and
manufacturers; the election by Intercept's collaborators to pursue
research, development and commercialization activities; Intercept's
ability to attract collaborators with development, regulatory and
commercialization expertise; Intercept's need for and ability to
obtain additional financing; Intercept's estimates regarding
expenses, revenues and capital requirements and the accuracy
thereof; Intercept's use of cash and short-term investments;
Intercept's ability to attract and retain key scientific or
management personnel; and other factors discussed under the heading
"Risk Factors" contained in our annual report on Form 10-K for the
year ended December 31, 2016 filed on March 1, 2017 as well as any
updates to these risk factors filed from time to time in our other
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Intercept undertakes no duty to update this information unless
required by law.
Contact
For more information about Intercept Pharmaceuticals, please
contact:
Mark Vignola+1-646-747-1000investors@interceptpharma.com
Christopher Frates+1-646-757-2371media@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024